• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
DAMGO

DAMGO

Product ID D0025
Cas No. 78123-71-4
Purity ≥95%
Product Unit SizeCostQuantityStock
1 mg $81.70 In stock
2 mg $138.90 In stock
5 mg $245.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

DAMGO is a synthetic peptide μ-opioid receptor agonist (μOR) that exhibits neuromodulatory and antinociceptive/analgesic activities. DAMGO decreases pain effects in animal models of visceral pain and also decreases motor activity in separate animal models. In vitro and in vivo, DAMGO decreases levels of the glutamate transporter EAAT3 and decreases GABA-A current.

Product Info

Cas No.

78123-71-4

Purity

≥95%

Formula

C26H35N5O6

Formula Wt.

513.0

IUPAC Name

(2S)-2-amino-N-[(2R)-1-[[2-[[(2S)-1-(2-hydroxyethylamino)-1-oxo-3-phenylpropan-2-yl]-methylamino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide

Synonym

DAGO, DAMGE

Solubility

Soluble in water (2 mg/mL).

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D0025 MSDS PDF

Info Sheet

D0025 Info Sheet PDF

References

Wu Q, Xia S, Lin J, et al. Effects of the altered activity of δ-opioid receptor on the expression of glutamate transporter type 3 induced by chronic exposure to morphine. J Neurol Sci. 2013 Dec 15;335(1-2):174-81. PMID: 24120272.

Alexeeva EV, Nazarova GA, Sudakov SK. Effects of peripheral μ, δ, and Κ-opioid receptor agonists on the levels of anxiety and motor activity of rats. Bull Exp Biol Med. 2012 Sep;153(5):720-1. PMID: 23113268.

Herman MA, Gillis RA, Vicini S, et al. Tonic GABAA receptor conductance in medial subnucleus of the tractus solitarius neurons is inhibited by activation of μ-opioid receptors. J Neurophysiol. 2012 Feb;107(3):1022-31. PMID: 22114164.

Al-Khrasani M, Lackó E, Riba P, et al. The central versus peripheral antinociceptive effects of μ-opioid receptor agonists in the new model of rat visceral pain. Brain Res Bull. 2012 Feb 10;87(2-3):238-43. PMID: 22079588.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • D0169

    Darifenacin Hydrobromide

    M3 mAChR antagonist.

    ≥98%
  • L3455

    α-Linolenic Acid

    An omega-3 fatty acid.

    ≥98%
  • A4935

    6-Aminocaproic Acid

    Protease inhibitor.

    ≥98%
  • O4578

    Oltipraz

    Antioxidant; Nrf2 activator.

    ≥98%
  • V014463

    Valsartan Methyl Ester

    Valsartan impurity

    ≥98%
  • U6801

    Urapidil

    5-HT1A agonist, α1-adrenergic antagonist.

    ≥98%
  • D6108

    1,4-DPCA

    Prolyl hydroxylase inhibitor.

    ≥98%
  • A5032

    D,L-Aminoglutethimide

    Aromatase inhibitor.

    ≥98%
  • Z161025

    β-Zearalenol

    Mycotoxin that has structural similarity to est...

    ≥98%
  • E0403

    Ebastine

    Histamine H1 antagonist.  
    ≥98%
  • N6076

    N(p-Tosyl)-GPR-pNA

    Thrombin substrate used to measure thrombin act...

    ≥95%
  • T0077

    Transactivator of Transcription Peptide (2-4)

    Peptide, contains two cell-penetrating sequence...

    ≥95%
  • C9773

    L-Cystine

    Endogenous amino acid, forms disulfide bridges ...

    ≥98%
  • O9210

    Oxcarbazepine

    α4β2 nAChR desensitizer, delayed-rectifier vo...

    ≥98%
  • F4503

    Flavokawain B

    Chalcone kavalactone that suppresses inflammation ...
    ≥97%
  • B564086

    Boceprevir

    Inhibits HCV replication

    ≥98%
  • U698574

    Urolithin A

    Ellagic acid derivative produced by gut microfl...

    ≥98%
  • U6957

    Urotensin I

    Endogenous peptide, involved in stress signalin...

    ≥95%
  • V0146

    Valsartan

    AT1 inhibitor.

    ≥98%
  • P0001

    P1 Peptide

    Octapeptide, prevents EGFR-PLCγ association.

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only